SJP-L-5, a novel small-molecule compound, inhibits HIV-1 infection by blocking viral DNA nuclear entry

BMC Microbiology

Table 1 Anti-HIV-1 activity of SJP-L-5

Strains^a	Subtypes	Tropisms	EC₅₀ (Mean ± SD)^b
Strains^a	Subtypes	Tropisms	SJP-L-5(μg/ml)	AZT^c(ng/ml)
HIV-1_IIIB	B	X4	0.16 ± 0.03	29.7 ± 9.7
HIV-1_MN	B	X4	0.97 ± 0.13	0.9 ± 0.1
HIV-1_RF	B	X4	0.18 ± 0.04	80.0 ± 25.5
HIV-1_KM018	CRF07_BC	R5	2.32 ± 0.41	37.7 ± 15.1
HIV-1_TC-2	CRF01_AE	X4	1.96 ± 0.22	5.0 ± 1.6
HIV-1_WAN	CRF07_BC/CRF01_AE	X4	5.33 ± 0.85	4.4 ± 1.5

^aHIV-1_IIIB, HIV-1_MN and HIV-1_RF are lab-adapted strains that infect C8166 cells, and they were used to measure the antiviral activity of SJP-L-5; HIV-1_KM018, HIV-1_TC-2, and HIV-1_WAN are clinical isolates that infect PBMC cells, and they were also used to measure the antiviral activity of SJP-L-5
^bn ≥ 3
^cAZT, azidothymidine

ISSN: 1471-2180